Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Globally, ovarian cancer is the eighth most common cancer in women, accounting for an
estimated 3.7% of cases and 4.7% of cancer deaths in 2020. Until the early 2000s, age …

Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the
ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive …

Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

PURPOSE To provide recommendations on the use of poly (ADP-ribose) polymerase
inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer …

Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …

Epithelial ovarian cancer (EOC) is one of the cancers most influenced by hereditary factors.
A fourth to a fifth of unselected EOC patients carry pathogenic variants (PVs) in a number of …